{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:42:27Z","timestamp":1783611747026,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The impact of sidedness on survival of later-line treatment in patients with metastatic colorectal cancer (mCRC) is undetermined. This study aimed to investigate the association between sidedness and survival among chemotherapy refractory patients with mCRC treated with trifluridine\/tipiracil (TAS-102) or regorafenib or both.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with mCRC treated with TAS-102 or regorafenib between 2015 and 2020 was retrospectively collected. Patients were stratified into TAS-102 first and regorafenib first, then subdivided into TAS-102 followed by regorafenib (T-R) and regorafenib followed by TAS-102 (R-T) groups. The oncologic outcomes were presented with time-to-treatment failure (TTF) and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After matching, 376 TAS-102 patients and 376 regorafenib patients were included for outcomes comparison. TTF had insignificant differences while OS was significantly different between TAS-102 and regorafenib groups. Median TTF and OS were 1.9 months versus 2.0 months (P\u2005=\u2005.701) and 9.1 months versus 7.0 months (P\u2005=\u2005.008) in TAS-102 and regorafenib, respectively. The OS benefits were consistent regardless primary tumor location. Subgroup analysis with 174 T-R patients and 174 R-T patients was investigated for treatment sequences. TTF and OS had significant differences in both groups. Median TTF and OS were 8.5 months versus 6.3 months (P\u2005=\u2005.001) and 14.4 months versus 12.6 months (P\u2005=\u2005.035) in T-R and R-T groups, respectively. The TTF and OS benefits were persisted regardless primary tumor location.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TAS-102 first provided a better survival benefit in chemotherapy refractory patients with mCRC across all sidedness. Further prospective studies are warranted to validate our conclusions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae235","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T21:54:11Z","timestamp":1723758851000},"page":"e1669-e1679","source":"Crossref","is-referenced-by-count":4,"title":["Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine\/tipiracil or regorafenib"],"prefix":"10.1093","volume":"29","author":[{"given":"Kai-Yuan","family":"Hsiao","sequence":"first","affiliation":[{"name":"Artificial Intelligence Development Center, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]},{"name":"Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Pao","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectum Surgery, Department of Surgery, E-Da Hospital , Kaohsiung ,","place":["Taiwan"]},{"name":"College of Medicine, I-Shou University , Kaohsiung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Ming","family":"Rau","sequence":"additional","affiliation":[{"name":"College of Medicine, I-Shou University , Kaohsiung ,","place":["Taiwan"]},{"name":"Department of Hematology-Oncology, E-Da Cancer Hospital , Kaohsiung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Wen","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectum Surgery, Department of Surgery, E-Da Hospital , Kaohsiung ,","place":["Taiwan"]},{"name":"College of Medicine, I-Shou University , Kaohsiung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-Chang","family":"Shia","sequence":"additional","affiliation":[{"name":"Artificial Intelligence Development Center, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]},{"name":"Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Shan","family":"Chang","sequence":"additional","affiliation":[{"name":"Artificial Intelligence Development Center, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]},{"name":"Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University , New Taipei City ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yun","family":"Liang","sequence":"additional","affiliation":[{"name":"College of Medicine, I-Shou University , Kaohsiung ,","place":["Taiwan"]},{"name":"EMMT Systems Corporation , Director ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-3396","authenticated-orcid":false,"given":"Meng-Che","family":"Hsieh","sequence":"additional","affiliation":[{"name":"College of Medicine, I-Shou University , Kaohsiung ,","place":["Taiwan"]},{"name":"Department of Hematology-Oncology, E-Da Cancer Hospital , Kaohsiung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"3","key":"2025022515400718500_CIT0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025022515400718500_CIT0002","author":"Cancer Stat Facts: Colon and Rectum Cancer","year":"2018"},{"issue":"1","key":"2025022515400718500_CIT0003","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2025022515400718500_CIT0004","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2025022515400718500_CIT0005","doi-asserted-by":"crossref","first-page":"v93","DOI":"10.1093\/annonc\/mdq222","article-title":"Advanced colorectal cancer: ESMO clinical practice guidelines for treatment","volume":"12","author":"Van Cutsem","year":"2010","journal-title":"Ann Oncol"},{"issue":"3","key":"2025022515400718500_CIT0006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2025022515400718500_CIT0007","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025022515400718500_CIT0008","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"2025022515400718500_CIT0009","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025022515400718500_CIT0010","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"31","key":"2025022515400718500_CIT0011","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025022515400718500_CIT0012","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025022515400718500_CIT0013","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"2025022515400718500_CIT0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ags3.12047","article-title":"Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe","volume":"2","author":"Shinagawa","year":"2017","journal-title":"Ann Gastroenterol Surg"},{"issue":"10","key":"2025022515400718500_CIT0015","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025022515400718500_CIT0016","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"2025022515400718500_CIT0017","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","article-title":"Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomized phase 3 trial","volume":"14","author":"Yamada","year":"2013","journal-title":"Lancet Oncol"},{"issue":"20","key":"2025022515400718500_CIT0018","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9863","key":"2025022515400718500_CIT0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previ- ously treated metastatic colorectal cancer (CORRECT): an international, multi- centre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet Oncol"},{"key":"2025022515400718500_CIT0020","first-page":"2","article-title":"An observational study of trifluridine\/tipiracil-containing regimen versus regorafenib-containing regimen in patients with metastatic colorectal cancer","volume":"12","author":"Meng-Che","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"2025022515400718500_CIT0021","first-page":"261","article-title":"A real-world comparison of regorafenib and trifluridine\/tipiracil in refractory metastatic colorectal cancer in the United States","volume":"21","author":"Christopher","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2025022515400718500_CIT0022","first-page":"233","article-title":"Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory metastatic colorectal cancer (mCRC) patients: a multi-institution real life clinical data","volume":"20","author":"Pasquale","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"2025022515400718500_CIT0023","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","article-title":"Taiwan\u2019s nationwide cancer registry system of 40 years: past, present, and future","volume":"118","author":"Chiang","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"2025022515400718500_CIT0024","first-page":"2","article-title":"A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer","volume":"48","author":"Guan-Li","year":"2020","journal-title":"J Int Med Res"},{"key":"2025022515400718500_CIT0025","doi-asserted-by":"crossref","first-page":"688709","DOI":"10.3389\/fonc.2021.688709","article-title":"Clinical impact of primary tumor location in metastatic colorectal cancer patients under later-line regorafenib or trifluridine\/tipiracil treatment","volume":"11","author":"Nakajima","year":"2021","journal-title":"Front Oncol"},{"issue":"18","key":"2025022515400718500_CIT0026","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Gerald","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2025022515400718500_CIT0027","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.21873\/anticanres.15033","article-title":"Regorafenib-to-trifluridine\/tipiracil versus the reverse sequence for refractory metastatic colorectal cancer patients: a multicenter retrospective real-life experience","volume":"41","author":"Signorelli","year":"2021","journal-title":"Anticancer Res"},{"issue":"6","key":"2025022515400718500_CIT0028","doi-asserted-by":"crossref","first-page":"e0269115","DOI":"10.1371\/journal.pone.0269115","article-title":"Influence of precedent drug on the subsequent therapy in the sequence of trifluridine\/tipiracil with\/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer","volume":"17","author":"Oshima","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"2025022515400718500_CIT0029","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clcc.2021.12.003","article-title":"Sequential treatment with trifluridine\/tipiracil and regorafenib in refractory metastatic colorectal cancer patients: an AGEO prospective \u201creal-world study.\u201d","volume":"21","author":"Coutzac","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"2025022515400718500_CIT0030","doi-asserted-by":"crossref","first-page":"576036","DOI":"10.3389\/fonc.2021.576036","article-title":"Survival benefit of crossover administration of regorafenib and trifluridine\/tipiracil hydrochloride for patients with metastatic colorectal cancer: exploratory analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)","volume":"11","author":"Chida","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"2025022515400718500_CIT0031","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.3390\/curroncol30060413","article-title":"Treatment settings and outcomes with regorafenib and trifluridine\/tipiracil at third-line treatment and beyond in metastatic colorectal cancer: a real-world multicenter retrospective study","volume":"30","author":"Signorelli","year":"2023","journal-title":"Curr Oncol"},{"issue":"8","key":"2025022515400718500_CIT0032","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/12\/e1669\/60952555\/oyae235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/12\/e1669\/60952555\/oyae235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:00:55Z","timestamp":1740499255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/12\/e1669\/7750792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae235","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,7]]}}}